Liver cancer - in particular, hepatocellular carcinoma (HCC) - is a complex disease, often detected in later stages, which leads to poorer patient outcomes. It is the third deadliest cancer in the world, killing 840,000 people each year1. Most patients with HCC have signs of advanced fibrosis, which is caused by chronic liver diseases, such as nonalcoholic fatty liver disease, alcoholic liver disease or viral hepatitis.
Although viral hepatitis is still the leading risk factor for HCC, it is expected that soon non-alcoholic fat liver disease (NAFLD) will become the leading cause for HCC2. Due to insufficient awareness within the general population, healthcare providers need to seek ways to detect disease earlier and ultimately improve outcomes.
With solutions along the entire patient pathway – from risk stratification, to diagnosis, treatment and survivorship – Siemens Healthineers sees as its mission to take up the fight against the world’s most deadly diseases.
As your partner in liver cancer management, Siemens Healthineers helps you accelerate the path from risk stratification, diagnosis, therapy and survivorship. In addition to driving speed and precision, our solutions seek to streamline workflows and empower cancer care teams to improve performance and meet unique and evolving patient needs.
Overcoming the challenges in liver cancer diagnosis and treatment
At the ECR 2023, Valérie Vilgrain, Chair of the Radiology Department at Beaujon Hospital in Paris, sat down with André Hartung, President of Diagnostic Imaging at Siemens Healthineers. In the video interview, they discuss how imaging can address the challenges in liver cancer diagnosis and treatment today.